Paper9683207
Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study.
Reijers MH and 12 others. Lancet, 1998. Cited by 138 papers, by iCite.
Cite this record
ConductScience Library. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Papers, record 9683207. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9683207
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-HIV Agents | Major topic |
| HIV Infections | Major topic |
| HIV-1 | Major topic |
| Adult | |
| CD4 Lymphocyte Count | |
| CD8-Positive T-Lymphocytes | |
| Drug Therapy, Combination | |
| Feasibility Studies | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Lymphocyte Count | |
| Male | |
| RNA, Viral | |
| Time Factors | |
| Virus Replication |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00084019 | Atazanavir/Ritonavir Maintenance Therapy | Background |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 9798619 | Amsterdam Duration of Antiretroviral Medication (ADAM) study. | https://conductscience.org/library/papers/9798619 |
Source PubMed
Cited by23
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 138 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39556960 | Risk of viral failure after simplification therapy without using integrase inhibitors compared with maintenance of triple antiretroviral therapy: A systematic review and meta-analysis. | Braz J Infect Dis | 2024 | https://conductscience.org/library/papers/39556960 | PubMed |
| 26872331 | Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens. | PLoS One | 2016 | https://conductscience.org/library/papers/26872331 | PubMed |
| 26849060 | Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients. | PLoS One | 2016 | https://conductscience.org/library/papers/26849060 | PubMed |
| 26677129 | Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients. | Drugs | 2016 | https://conductscience.org/library/papers/26677129 | PubMed |
| 24802242 | Baseline natural killer and T cell populations correlation with virologic outcome after regimen simplification to atazanavir/ritonavir alone (ACTG 5201). | PLoS One | 2014 | https://conductscience.org/library/papers/24802242 | PubMed |
| 21034506 | Predictors of adherence to antiretroviral therapy among people living with HIV/AIDS in resource-limited setting of southwest ethiopia. | AIDS Res Ther | 2010 | https://conductscience.org/library/papers/21034506 | PubMed |
| 20064271 | Modelling imperfect adherence to HIV induction therapy. | BMC Infect Dis | 2010 | https://conductscience.org/library/papers/20064271 | PubMed |
| 19787058 | The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. | PLoS One | 2009 | https://conductscience.org/library/papers/19787058 | PubMed |
| 19320232 | Simplification strategies to reduce antiretroviral drug exposure: progress and prospects. | Antivir Ther | 2009 | https://conductscience.org/library/papers/19320232 | PubMed |
| 17630827 | Optimal timing and duration of induction therapy for HIV-1 infection. | PLoS Comput Biol | 2007 | https://conductscience.org/library/papers/17630827 | PubMed |
| 16920824 | Possible therapeutic vaccine strategy against human immunodeficiency virus escape from reverse transcriptase inhibitors studied in HLA-A2 transgenic mice. | J Virol | 2006 | https://conductscience.org/library/papers/16920824 | PubMed |
| 14766874 | Different viral rebound following discontinuation of antiretroviral therapy in cases of infection with viruses carrying L74V or thymidine-associated mutations. | J Clin Microbiol | 2004 | https://conductscience.org/library/papers/14766874 | PubMed |
| 14583945 | Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection. | Cochrane Database Syst Rev | 2003 | https://conductscience.org/library/papers/14583945 | PubMed |
| 12866987 | When to Start Antiretroviral Therapy and What to Start With-- A European Perspective. | Curr Infect Dis Rep | 2003 | https://conductscience.org/library/papers/12866987 | PubMed |
| 12204968 | Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients. | Clin Diagn Lab Immunol | 2002 | https://conductscience.org/library/papers/12204968 | PubMed |
| 12000245 | Accelerated publication versus usual publication in 2 leading medical journals. | CMAJ | 2002 | https://conductscience.org/library/papers/12000245 | PubMed |
| 11782542 | Structured intermittent treatment for HIV disease: Necessary concession or premature compromise? | Proc Natl Acad Sci U S A | 2002 | https://conductscience.org/library/papers/11782542 | PubMed |
| 11095802 | Reservoirs for HIV-1. | Curr Infect Dis Rep | 1999 | https://conductscience.org/library/papers/11095802 | PubMed |
| 10727446 | Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA. | J Clin Invest | 2000 | https://conductscience.org/library/papers/10727446 | PubMed |
| 10721504 | Design of dimerization inhibitors of HIV-1 aspartic proteinase: a computer-based combinatorial approach. | J Comput Aided Mol Des | 2000 | https://conductscience.org/library/papers/10721504 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9683207
GET https://conductscience.org/api/papers/v1/9683207/cited_by?page=2